Oxford BioMedica PLC
OXB
Company Profile
Business description
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
Contact
Transport Way
Windrush Court
OxfordOX4 6LT
GBRT: +44 1865783000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
986
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 27.30 | -0.30% |
| CAC 40 | 8,430.79 | 16.48 | -0.20% |
| DAX 40 | 24,934.67 | 24.26 | 0.10% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,508.61 | 14.40 | 0.14% |
| HKSE | 23,900.01 | 412.15 | -1.70% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 71,316.33 | 1,414.08 | 2.02% |
| NZX 50 Index | 13,359.82 | 33.16 | -0.25% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,924.60 | 24.10 | -0.27% |
| SSE Composite Index | 4,092.76 | 15.31 | -0.37% |